TomoTherapy to Offer Advanced Radiation Therapy Solution to GNYHA Services Member Hospitals
MADISON, Wis – Sept. 10, 2009 – TomoTherapy Incorporated (NASDAQ: TOMO), maker of the TomoTherapy® treatment system for advanced, CT-guided radiation therapy, announced today that it has signed an equipment supply group purchasing agreement with GNYHA Services, Inc. Pursuant to this agreement, TomoTherapy technology will be made available at contracted rates to more than 220 member hospitals in New York, New Jersey, Pennsylvania and Puerto Rico.
Fred Robertson, TomoTherapy CEO, said, “It is an honor to work with GNYHA Services, the largest regional group purchasing organization in the country. GNYHA Services is committed to helping its member hospitals improve healthcare quality. The TomoTherapy treatment system will certainly help GNYHA Services fulfill this goal.”
GNYHA Services was founded in 1978 as the for-profit group purchasing arm of the Greater New York Hospital Association (GNYHA), a trade association that dates back to 1904.
In 1996, GNYHA Services partnered with Premier Purchasing Partners, L.L.P., one of the largest voluntary healthcare alliances in the U.S., to offer unsurpassed value and financial return to its members through access to Premier’s comprehensive contract portfolio. Through the oversight of Giuliani Partners, L.L.C., this relationship was extended in 2004, with a renewed focus on flexibility in regionally-enhanced and direct contracting by GNYHA.
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
10 Sep 2009
| Investor Contact: Thomas E. Powell Chief Financial Officer 608.824.2800 tpowell@tomotherapy.com |
Media Contact: Kevin O’Malley Manager Corporate Communications 608.824.2800 komalley@tomotherapy.com |
